Research & Development
Cell-free DNA methylation blood test predicts risk of early-onset preeclampsia
Cell-free DNA methylation profiling may support the presymptomatic assessment of preeclampsia (PE) risk, according to a paper published on August 28 in Nature Medicine.
August 30, 2023
Blood test predicts severe preeclampsia during pregnancy
An FDA-approved blood test helps doctors more accurately predict whether a woman will develop severe preeclampsia during pregnancy, according to its developers.
June 14, 2023
Thermo Fisher Scientific obtains FDA clearance for preeclampsia risk immunoassays
The new assays are the first and only such immunoassays to receive breakthrough designation and clearance for preeclampsia risk assessment and management, the company noted in a statement.
May 19, 2023
Research shows biomarkers may provide early warning for pregnancy complications
Researchers have identified biomarkers in blood samples that could provide an early warning system for three common and dangerous pregnancy complications.
January 12, 2023
Biora Therapeutics, Avero Diagnostics to develop preeclampsia rule-out test
Under the terms of an agreement, Biora would receive milestone payments and royalties on net sales if the test reaches the market.
November 29, 2022
Week in Review: Getting to know COVID-19 | Biomarkers for preeclampsia, liver disease | Quest puts HPV/Pap cotesting to the test
Dear LabPulse Member,
July 9, 2020
Blood biomarkers show risk for preeclampsia in pregnant women
The proof-of-concept study looked at the levels and ratio of the proteins FK506-binding protein like (FKBPL) and cluster of differentiation 44 (CD44) in plasma of pregnant women and matched normal controls at the Royal Jubilee Maternity Hospital in Belfast, U.K., and how they associated with risk for preeclampsia.
July 7, 2020
Page 1 of 1